Vaxcyte (PCVX) to Release Earnings on Wednesday

Vaxcyte (NASDAQ:PCVX) is expected to issue its Q2 2026 results before the market opens on Wednesday, August 5th. Analysts expect Vaxcyte to post earnings of ($2.0556) per share and revenue of $12.50 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Friday, August 7, 2026 at 4:00 PM ET.

Vaxcyte (NASDAQ:PCVX) last announced its earnings results on Wednesday, May 6th. The company reported ($2.30) EPS for the quarter, missing analysts’ consensus estimates of ($1.74) by ($0.56). During the same period last year, the company posted ($1.04) EPS. On average, analysts expect Vaxcyte to post $-8 EPS for the current fiscal year and $-7 EPS for the next fiscal year.

Vaxcyte Trading Down 1.6%

NASDAQ PCVX opened at $54.60 on Wednesday. The firm’s fifty day simple moving average is $52.83 and its two-hundred day simple moving average is $54.77. Vaxcyte has a 12-month low of $29.08 and a 12-month high of $65.00. The firm has a market capitalization of $7.88 billion, a P/E ratio of -7.94 and a beta of 1.22.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the stock. Wall Street Zen downgraded shares of Vaxcyte from a “sell” rating to a “strong sell” rating in a research report on Tuesday, April 28th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vaxcyte in a research note on Monday, July 6th. Finally, Zacks Research lowered Vaxcyte from a “hold” rating to a “strong sell” rating in a research report on Tuesday, July 14th. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $86.00.

Insiders Place Their Bets

In related news, COO Jim Wassil sold 2,250 shares of the stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $49.52, for a total transaction of $111,420.00. Following the completion of the transaction, the chief operating officer owned 158,494 shares of the company’s stock, valued at approximately $7,848,622.88. This trade represents a 1.40% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew Guggenhime sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, July 6th. The shares were sold at an average price of $57.28, for a total value of $572,800.00. Following the completion of the sale, the chief financial officer directly owned 104,395 shares in the company, valued at approximately $5,979,745.60. The trade was a 8.74% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 93,646 shares of company stock valued at $5,103,592 in the last ninety days. 3.30% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Vaxcyte

Large investors have recently bought and sold shares of the stock. Amundi purchased a new stake in Vaxcyte in the 4th quarter valued at $235,000. Farallon Capital Management LLC acquired a new stake in shares of Vaxcyte during the fourth quarter worth about $231,000. Caxton Associates LLP acquired a new position in Vaxcyte in the 1st quarter valued at about $226,000. Cubist Systematic Strategies LLC purchased a new stake in Vaxcyte during the 1st quarter valued at approximately $219,000. Finally, Empowered Funds LLC purchased a new stake in shares of Vaxcyte during the fourth quarter worth approximately $211,000. Institutional investors and hedge funds own 96.78% of the company’s stock.

Vaxcyte Company Profile

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.